CVS Health Corporation

Valuation Analysis

About the Company

CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, includi

CVS Health Corporation Stock at a Glance

CVS Health Corporation (CVS) is currently trading at $101.96 with a market capitalization of $130.1B. The trailing P/E ratio stands at 44.72x, with a forward P/E of 12.18x. The 52-week range spans from $58.50 to $102.77; the current price is 0.8% below the yearly high. Year-over-year revenue growth stands at +6.1%. The net profit margin stands at 0.72%.

💰 Dividend

CVS Health Corporation pays an annual dividend of $2.66 per share, representing a yield of 2.61%. The payout ratio stands at 116.67%. The elevated payout ratio reflects a mature dividend policy.

📊 Analyst Rating

26 analysts rate CVS Health Corporation (CVS) on consensus: Strong Buy. The average price target is $104.50, implying +2.49% from the current price. Analyst price targets range from $79.00 to $140.00.

CVS Health Corporation: The Investment Case in Detail

CVS Health Corporation (CVS) operates in the Healthcare — specifically Healthcare Plans — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 63.1% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base.

The Bear Case

With a net margin of just 0.72%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

With a PEG ratio of 0.29, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 12.18x is meaningfully below the trailing 44.72x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 98.2% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy CVS Health Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.